Clarification of MPC and the mutant selection window concept [1]

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 731-

  Zhao, Xilin ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Antimicrobial resistance; Limitation; Mechanism

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACTIVITY; GENE MUTATION; GENETIC RESISTANCE; HUMAN; HYPOTHESIS; LETTER; MEASUREMENT; MONOTHERAPY; NONHUMAN; PRACTICE GUIDELINE; PREVENTION; TREATMENT PLANNING;

DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 0141928522     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg376     Document Type: Letter

References (5)

1. Smith, H. J., Nichol, K. A., Hoban, D. J. et al. (2003). Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy 51, 1323-5.
2. Baquero, F. & Negri, M. C. (1997). Strategies to minimize the development of antibiotic resistance. Journal of Chemotherapy 9, Suppl., 29-37.
3. Zhou, J.-F., Dong, Y., Zhao, X. et al. (2000). Selection of antibiotic resistance: allelic diversity among fluoroquinolone-resistant mutations. Journal of Infectious Diseases 182, 517-25.
4. Zhao, X. & Drlica, K. (2002). Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. Journal of Infectious Diseases 185, 561-5.
5. Sindelar, G., Zhao, X., Liew, A. et al. (2000). Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrobial Agents and Chemotherapy 44, 3337-43.